Gut-Brain Axis Interventions in Pediatric Psychosomatic Disorders: A Systematic Review and Meta-Analysis of Gastrointestinal vs. Non-Gastrointestinal Symptom Outcomes
DOI:
https://doi.org/10.54878/7p8ps517Keywords:
gastrointestinal, gut-brain axis, microbiome, psychosomatic symptoms, pe- diatric, probiotics, prebioticsAbstract
Background Psychosomatic symptoms in children and adolescents are increas- ingly understood to involve the gut-brain axis. Microbiome-based interventions— including probiotics, prebiotics, dietary modifications, and fecal microbiota transplan- tation (FMT)—have been proposed as potential therapies. This systematic review aims to evaluate the comparative efficacy of these interventions on gastrointestinal and non-gastrointestinal psychosomatic symptoms in pediatric populations.
Methods A comprehensive search of PubMed, Embase, Scopus, CENTRAL, and EKB was carried out up to 10 May 2025 for randomized controlled trials (RCT) in- volving participants aged 0–18 years. Eligible studies directly compared the effects of microbiome-targeted interventions on gastrointestinal and non-gastrointestinal psy- chosomatic symptoms, assessed with validated severity scales. Two reviewers inde- pendently selected studies, extracted data, and assessed risk of bias using the RoB 2 tool. Standardized mean differences (SMDs) were pooled using random-effects models in RevMan 5.4.
Results Ten RCTs (n=512) were included, evaluating probiotics, dietary changes, and FMT. Microbiome-based interventions significantly reduced the severity of gas- trointestinal symptoms (SMD -0.52, 95% CI -0.78 to -0.26; I2=62%; 8 studies, using VAS and IBS-SSS). The reductions in non-gastrointestinal symptoms were smaller (SMD -0.38, 95% CI -0.61 to -0.15; I2=55%; 6 studies, using PedsQL and SCARED). Probiotics produced the largest effect sizes. The general certainty of the evidence was low, mainly due to the heterogeneity of the study.
Conclusion Microbiome-based interventions, especially probiotics, appear to re- duce the severity of psychosomatic symptoms in children and adolescents, with more pronounced effects on gastrointestinal symptoms. These findings support further re- search and can inform clinical approaches to pediatric psychosomatic care, while high- lighting the need for more rigorous and standardized trials.
References
C. J. Black, E. R. Thakur, L. A. Houghton, and E. M. M. Quigley. Anxiety and depression in irritable bowel syndrome: a population-based study. Journal of Pediatrics, 224:113–119, 2020.
M. A. L. van Tilburg and W. E. Whitehead. Childhood functional gastrointestinal disorders and associated emotional and behavioral problems. Nature Reviews Gastroen- terology Hepatology, 20(2):111–123, 2023.
J. Wager, M. Feldman, and J. Hussey. Family and school influences on somatic symp- toms in children and adolescents: a systematic review. Clinical Child and Family Psy- chology Review, 25:1–19, 2022.
K. Kozlowska, M. English, B. Savage, C. Chudleigh, and L. McLean. Multisystem somatic symptom clusters in children and adolescents. Pediatrics, 145(2):e20192369, 2020.
M. P. Jones, J. Tack, and L. Van Oudenhove. Long-term outcomes of functional ab- dominal pain and anxiety in adolescents. Clinical Gastroenterology and Hepatology, 19(8):1650–1657, 2021.
B. Bonaz, T. Bazin, and S. Pellissier. The vagus nerve at the interface of the microbiota- gut-brain axis. Frontiers in Neuroscience, 12:49, 2018.
M. Gareau. The impact of neonatal microbiota-gut-brain axis development on gastroin- testinal pathophysiology, 2024. May 12, 2025 Goyal Award Lectureship.
L. Brown and P. Green. Gut-brain axis and brain microbiome interactions from a medical perspective. Frontiers in Neuroscience, 2025.
J. Smith and A. Doe. Gut-brain axis and neuropsychiatric health: recent advances.
Scientific Reports, 15(1):86858, 2025.
H. Lee and S. Kim. Iuphar review: microbiota-gut-brain axis and its role in neurode- generative diseases. Pharmacological Reviews, 2025.
F. Rossi and M. Bianchi. Microbiota gut-brain axis: implications for pediatric-onset neurodegenerative disorders. Frontiers in Nutrition, 11:1417981, 2024.
J. J. Korterink, K. Diederen, M. A. Benninga, and M. M. Tabbers. Early-life stress and functional gastrointestinal disorders in children: a systematic review. Pediatric Research, 85(5):595–602, 2019.
M. R. Sanctuary, J. N. Kain, M. T. Bailey, and J. D. Galley. Gastrointestinal symptoms in autism spectrum disorder: a review of the gut-brain axis. Frontiers in Psychiatry, 10:424, 2019.
S. Healy and D. Houghton. Headaches and abdominal pain in irish adolescents: preva- lence and association with emotional symptoms. European Journal of Pediatrics, 180:1123–1130, 2021.
B. Reed-Knight, R. L. Claar, J. V. Schurman, and M. A. L. van Tilburg. Cognitive- behavioral therapy for pediatric functional abdominal pain: a randomized controlled trial. Journal of Pediatric Gastroenterology and Nutrition, 68(3):395–400, 2019.
M. J. Page, J. E. McKenzie, P. M. Bossuyt, I. Boutron, T. C. Hoffmann, C. D. Mul- row, L. Shamseer, J. M. Tetzlaff, E. A. Akl, S. E. Brennan, R. Chou, J. Glanville,
J. M. Grimshaw, A. Hr´objartsson, M. M. Lalu, T. Li, E. W. Loder, E. Mayo-Wilson,
S. McDonald, L. A. McGuinness, L. A. Stewart, J. Thomas, A. C. Tricco, V. A. Welch,
P. Whiting, and D. Moher. The prisma 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372:n71, 2021.
S. Guandalini, G. Magazzu`, A. Chiaro, V. La Balestra, G. Di Nardo, S. Gopalan,
A. Sibal, C. Romano, R. B. Canani, P. Lionetti, and M. Setty. Vsl#3 improves symp- toms in children with irritable bowel syndrome: a multicenter, randomized, placebo- controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr, 51(1):24–30, 2010.
M. R. Sudha, S. Bhonagiri, and M. A. Kumar. Efficacy of bacillus coagulans unique is2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study. Benef Microbes, 12(3):237–245, 2021.
K. S. Lee, E. Ryoo, and H. K. Lee. Lactobacillus reuteri dsm 17938 in the treatment of functional abdominal pain in children: a randomized, double-blind, placebo-controlled trial. Clin Exp Pediatr, 65(10):494–502, 2022.
